ME01718B - Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C - Google Patents

Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C

Info

Publication number
ME01718B
ME01718B MEP-2014-23A MEP2314A ME01718B ME 01718 B ME01718 B ME 01718B ME P2314 A MEP2314 A ME P2314A ME 01718 B ME01718 B ME 01718B
Authority
ME
Montenegro
Prior art keywords
pharmaceutical composition
hepatitis
protease inhibitor
viral protease
pharmaceutically acceptable
Prior art date
Application number
MEP-2014-23A
Other languages
English (en)
Inventor
Robert J Schwabe
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ME01718B publication Critical patent/ME01718B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

"(12) PATENTNI SPIS<br /> 1 <br />me<br />B 01718 ME<br />(11)<br />ME 01718B (19) Crna Gora<br />(21) Broj prijave: P-2014-23<br />(22) Datum podnošenja prijave: 01. 07. 2010<br />(45) Datum objavljivanja patenta: 20. 09. 2014<br /> Glasnik : 15/2014<br /> (51) Me dunarodna klasifikacija MKP<br />A61K9/107<br />2006.01<br />A61K9/48<br />2006.01<br />A61K31/427<br />2006.01<br />A61K47/10<br />2006.01<br />A61K47/12<br />2006.01<br />A61K47/14<br />2006.01<br />A61K47/44<br />2006.01<br />(30) Me dunarodno pravo prvenstva<br />US<br />20090223507P<br />07. 07. 2009<br />(96) Broj i datum prijave evropskog patenta:<br />EP<br />10731685.3<br />01. 07. 2010<br />(86) Broj i datum me dunarodne prijave:<br />US<br />PCT/US2010/040734<br />(73) Nosilac Patenta<br />Boehringer Ingelheim International GmbH<br />Binger Strasse 173<br />55216 Ingelheim am Rhein<br />DE<br />(74) Zastupnik:<br />RADULOVI C, S. Božidar<br />Studentska bb, Lamela 3/18<br />Podgorica<br />81000<br />ME<br /> (72) Pronalaza c<br />CHEN, Feng-Jing<br />Boehringer Ingelheim Pharmaceuticals Inc., 900 <br />Ridgebury Road, P.O. Box 368<br />Ridgefield Connecticut 06877-0368<br />US<br />SCHWABE, Robert J.<br />Boehringer Ingelheim Pharmaceuticals Inc., 900 <br />Ridgebury Road, P.O. Box 368<br />Ridgefield Connecticut 06877-0368<br />US<br />(54) Naziv:<br />me<br />Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C<br />en<br />Pharmaceutical composition for a hepatitis C viral protease inhibitor"

Claims (1)

1. Tečna farmaceutska kompozicija koja sadrži:(a) jedinjenje formule (1):ili njegovu farmaceutski prihvatljivu so; (b) jedan ili više farmaceutskih prihvatljivih lipida; i(c) jednu ili više farmaceutski prihvatljivih hidrofilnih površinski aktivnih supstanci.
MEP-2014-23A 2009-07-07 2010-07-01 Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C ME01718B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22350709P 2009-07-07 2009-07-07
EP10731685.3A EP2451438B8 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis c viral protease inhibitor
PCT/US2010/040734 WO2011005646A2 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis c viral protease inhibitor

Publications (1)

Publication Number Publication Date
ME01718B true ME01718B (me) 2014-09-20

Family

ID=43245003

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2014-23A ME01718B (me) 2009-07-07 2010-07-01 Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C

Country Status (35)

Country Link
US (1) US9034831B2 (me)
EP (1) EP2451438B8 (me)
JP (1) JP5607736B2 (me)
KR (1) KR101685941B1 (me)
CN (1) CN102470103B (me)
AP (1) AP2011005979A0 (me)
AR (1) AR077393A1 (me)
AU (1) AU2010270783B2 (me)
BR (1) BR112012000287B8 (me)
CA (1) CA2767692C (me)
CL (1) CL2012000054A1 (me)
CO (1) CO6480980A2 (me)
DK (1) DK2451438T3 (me)
EA (1) EA023433B1 (me)
EC (1) ECSP12011624A (me)
ES (1) ES2464367T3 (me)
GE (1) GEP20146016B (me)
HR (1) HRP20140445T1 (me)
IL (1) IL216098A (me)
MA (1) MA33491B1 (me)
ME (1) ME01718B (me)
MX (1) MX2011013824A (me)
MY (1) MY154683A (me)
NZ (1) NZ596928A (me)
PE (1) PE20120322A1 (me)
PL (1) PL2451438T3 (me)
PT (1) PT2451438E (me)
RS (1) RS53209B (me)
SG (1) SG177569A1 (me)
SI (1) SI2451438T1 (me)
TN (1) TN2012000009A1 (me)
TW (1) TWI490216B (me)
UA (1) UA104195C2 (me)
UY (1) UY32760A (me)
WO (1) WO2011005646A2 (me)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2337583A1 (en) * 2008-09-17 2011-06-29 Boehringer Ingelheim International GmbH Combination of hcv ns3 protease inhibitor with interferon and ribavirin
WO2011005646A2 (en) 2009-07-07 2011-01-13 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
AP2013006734A0 (en) 2010-09-30 2013-02-28 Boehringer Ingelheim Int Combination therapy for treating HCV infection
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
MX2014008205A (es) 2012-01-12 2014-08-08 Boehringer Ingelheim Int Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv.
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
CN105228593B (zh) * 2013-03-15 2018-08-28 勃林格殷格翰国际有限公司 呈无定形状态的hcv抑制剂的固体口服剂型
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
AU2021253796B2 (en) 2020-04-05 2023-06-01 Pfizer Inc. Compounds and methods for the treatment of COVID-19

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445174B (sv) 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
US5329976A (en) 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
ES2308955T5 (es) 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
EP0825849A1 (en) 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
NZ502566A (en) * 1997-07-29 2002-03-28 Upjohn Co Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation containing a pyranone and a basic amine
CA2294032A1 (en) 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
CN1208047C (zh) * 1997-07-29 2005-06-29 法玛西雅厄普约翰美国公司 亲脂性化合物的自体乳化剂
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6710195B2 (en) 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
UA81028C2 (en) 2003-04-02 2007-11-26 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis c viral protease inhibitors
HRP20080014T3 (en) * 2003-05-21 2008-02-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
JP4654239B2 (ja) 2004-03-15 2011-03-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法
AU2005228894B9 (en) 2004-03-30 2011-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005116054A1 (en) 2004-05-25 2005-12-08 Boehringer Ingelheim International, Gmbh Process for preparing acyclic hcv protease inhibitors
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
AU2009293494B2 (en) 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
RS53121B (sr) 2008-11-21 2014-06-30 Boehringer Ingelheim International Gmbh Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primenu
WO2011005646A2 (en) 2009-07-07 2011-01-13 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor

Also Published As

Publication number Publication date
UA104195C2 (ru) 2014-01-10
EA201200096A1 (ru) 2012-08-30
RS53209B (sr) 2014-06-30
CN102470103B (zh) 2016-09-07
HRP20140445T1 (hr) 2014-06-20
US9034831B2 (en) 2015-05-19
SI2451438T1 (sl) 2014-04-30
GEP20146016B (en) 2014-01-27
EP2451438A2 (en) 2012-05-16
CN102470103A (zh) 2012-05-23
TN2012000009A1 (en) 2013-09-19
PT2451438E (pt) 2014-03-26
AP2011005979A0 (en) 2011-12-31
DK2451438T3 (da) 2014-03-10
IL216098A (en) 2016-02-29
JP5607736B2 (ja) 2014-10-15
TW201114766A (en) 2011-05-01
BR112012000287B8 (pt) 2021-05-25
MA33491B1 (fr) 2012-08-01
UY32760A (es) 2011-02-28
CA2767692A1 (en) 2011-01-13
KR101685941B1 (ko) 2016-12-13
CA2767692C (en) 2017-03-07
MX2011013824A (es) 2012-01-30
US20110160149A1 (en) 2011-06-30
AR077393A1 (es) 2011-08-24
NZ596928A (en) 2013-05-31
BR112012000287A2 (pt) 2016-02-23
ECSP12011624A (es) 2012-02-29
CL2012000054A1 (es) 2012-10-12
AU2010270783B2 (en) 2013-06-27
EP2451438B8 (en) 2014-04-09
JP2012532192A (ja) 2012-12-13
ES2464367T3 (es) 2014-06-02
MY154683A (en) 2015-07-15
CO6480980A2 (es) 2012-07-16
WO2011005646A2 (en) 2011-01-13
BR112012000287B1 (pt) 2020-12-08
KR20120059481A (ko) 2012-06-08
AU2010270783A1 (en) 2011-12-15
TWI490216B (zh) 2015-07-01
PL2451438T3 (pl) 2014-07-31
IL216098A0 (en) 2012-01-31
SG177569A1 (en) 2012-03-29
PE20120322A1 (es) 2012-04-14
EA023433B1 (ru) 2016-06-30
WO2011005646A3 (en) 2011-12-22
EP2451438B1 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
EP2100610A4 (en) PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2&#39;,3&#39;-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
SE0302487D0 (sv) Novel compounds
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
UY29182A1 (es) &#34;derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones&#34;
BRPI0407097A (pt) Antagonista do casr
UY30903A1 (es) Nuevas sformas de sales de n-[2-(dietilamino)etil]-n-(2-{[2-(4-hidorxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida, composiciones comprendiéndolas, procesos de preparacion y aplicaciones.
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
AR059357A1 (es) Formulaciones farmaceuticas
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse
AR056014A1 (es) Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo
BRPI0620229A8 (pt) formulação
AR060733A1 (es) Proceso para la precipitacion y el aislamiento de compuestos de 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen los mismos
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
FR2897866B1 (fr) Forme cristalline alpha du sel d&#39;arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2&#39;cloro-6&#39;-fluoroanilino)fenilacético
BRPI0607918A2 (pt) tetraidro-piridoazepin-8-onas e compostos relacionados para o tratemento da esquizofrenia.
DK1853241T3 (da) Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion ved behandling af Parkinson&#39;s sygdom
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto